Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robots and dye could spare testicular cancer patients unnecessary treatment

NCT ID NCT06133543

Diagnosis Sponsor: Heinrich-Heine University, Duesseldorf Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new, less invasive way to check if testicular cancer has spread. Doctors inject a dye into the testicle, then use a robot to find and remove the first lymph node that drains the tumor. The goal is to see if this method is accurate enough to replace more extensive treatments. The trial will enroll 44 adults with early-stage testicular cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Indocyanine green (ICG) dye
What this could lead to
If successful, this technique could become a new standard for staging testicular cancer, helping doctors avoid unnecessary treatments and their side effects.
What could go wrong
This is a small, early feasibility study with only 44 participants. The technique may not achieve the desired 90% sensitivity, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically confirmed unequivocal testicular tumor by palpation and sonography with or without elevation of specific tumor markers AFP and/or ß-HCG. * Clinical exclusion of metastases in preoperative staging using contrast-enhanced CT of the thorax and abdomen. * The patient is of legal age. * The patient can communicate with the investigator without issues or limitations and can understand and sign the patient information and consent form without problems or limitations. Exclusion Criteria: * Testicular tumor with uncertain dignity * Patients with small testicular masses (\< 1 cm) * Patients with prior scrotal or retroperitoneal surgery for reasons other than a germ cell tumor. * The patient has received different chemotherapy. * The patient has undergone retroperitoneal radiotherapy. * Exclusion criteria for the use of ICG include a history of anaphylactic reactions to ICG and iodine intolerance (ICG solution contains sodium iodide). * The patient is in a reduced general condition or has a life-threatening illness. * The patient has a psychiatric illness.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Germ cell tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

germ cell tumor Neoplasms, Germ Cell and Embryonal nongerminomatous germ cell tumor Nonseminomatous germ cell tumor seminoma testicular cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Germ cell tumor Nonseminomatous germ cell tumor Seminoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Duesseldorf

    RECRUITING

    Düsseldorf, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.